XML 58 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segments of Business and Geographic Areas | 9 Months Ended
--- | ---
Sep. 29, 2013
Segment Reporting [Abstract] |
SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 1,225 |  |  | $ | 1,214 |  |  | 0.9 | %
International |  | 2,386 |  |  | 2,367 |  |  | 0.8 |
Total |  | 3,611 |  |  | 3,581 |  |  | 0.8 |
Pharmaceutical |  |  |  |  |  |
United States |  | 3,549 |  |  | 3,288 |  |  | 7.9 |
International |  | 3,487 |  |  | 3,114 |  |  | 12.0 |
Total |  | 7,036 |  |  | 6,402 |  |  | 9.9 |
Medical Devices & Diagnostics |  |  |  |  |  |
United States |  | 3,151 |  |  | 3,289 |  |  | (4.2 | )
International |  | 3,777 |  |  | 3,780 |  |  | (0.1 | )
Total |  | 6,928 |  |  | 7,069 |  |  | (2.0 | )
Worldwide |  |  |  |  |  |
United States |  | 7,925 |  |  | 7,791 |  |  | 1.7 |
International |  | 9,650 |  |  | 9,261 |  |  | 4.2 |
Total |  | $ | 17,575 |  |  | $ | 17,052 |  |  | 3.1 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 3,899 |  |  | $ | 3,843 |  |  | 1.5 | %
International |  | 7,045 |  |  | 6,952 |  |  | 1.3 |
Total |  | 10,944 |  |  | 10,795 |  |  | 1.4 |
Pharmaceutical |  |  |  |  |  |
United States |  | 10,397 |  |  | 9,408 |  |  | 10.5 |
International |  | 10,432 |  |  | 9,418 |  |  | 10.8 |
Total |  | 20,829 |  |  | 18,826 |  |  | 10.6 |
Medical Devices & Diagnostics |  |  |  |  |  |
United States |  | 9,600 |  |  | 9,119 |  |  | 5.3 |
International |  | 11,584 |  |  | 10,926 |  |  | 6.0 |
Total |  | 21,184 |  |  | 20,045 |  |  | 5.7 |
Worldwide |  |  |  |  |  |
United States |  | 23,896 |  |  | 22,370 |  |  | 6.8 |
International |  | 29,061 |  |  | 27,296 |  |  | 6.5 |
Total |  | $ | 52,957 |  |  | $ | 49,666 |  |  | 6.6 | %
SEGMENT PRE-TAX PROFIT
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
Consumer |  | $ | 467 |  |  | $ | 510 |  |  | (8.4 | )%
Pharmaceutical (2) |  | 2,449 |  |  | 1,388 |  |  | 76.4 |
Medical Devices & Diagnostics(3) |  | 956 |  |  | 1,927 |  |  | (50.4 | )
Segments operating profit |  | 3,872 |  |  | 3,825 |  |  | 1.2 |
Less: Expense not allocated to segments(4) |  | 205 |  |  | 230 |  |  |
Worldwide income before taxes |  | $ | 3,667 |  |  | $ | 3,595 |  |  | 2.0 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
Consumer (1) |  | $ | 1,525 |  |  | $ | 1,239 |  |  | 23.1 | %
Pharmaceutical (2) |  | 7,858 |  |  | 4,494 |  |  | 74.9 |
Medical Devices & Diagnostics (3) |  | 3,991 |  |  | 5,880 |  |  | (32.1 | )
Segments operating profit |  | 13,374 |  |  | 11,613 |  |  | 15.2 |
Less: Expense not allocated to segments (4) |  | 653 |  |  | 938 |  |  |
Worldwide income before taxes |  | $ | 12,721 |  |  | $ | 10,675 |  |  | 19.2 | %
(1) Includes a gain on the sale of intangible and other assets of $55 million recorded in the fiscal nine months of 2013. Includes intangible asset write-downs of $294 million recorded in the fiscal nine months of 2012. (2) Includes in-process research and development charges of $178 million and litigation expense of $28 million recorded in the fiscal third quarter of 2013. Includes litigation expense of $206 million, in-process research and development charges of $178 million and a net gain of $400 million on equity investment transactions, primarily the sale of Elan American Depositary Shares recorded in the fiscal nine months of 2013. Includes in-process research and development charges of $679 million recorded in the fiscal third quarter of 2012. Includes in-process research and development charges of $1,108 million, litigation expense of $658 million and intangible asset write-downs of $499 million recorded in the fiscal nine months of 2012. (3) Includes litigation expense of $844 million, Synthes integration/transaction costs of $122 million and $35 million for the ASR™ Hip program recorded in the fiscal third quarter of 2013. Includes litigation expense of $1,564 million, Synthes integration/transaction costs of $502 million, in-process research and development charges of $64 million and $117 million for the ASR™ Hip program in the fiscal nine months of 2013. Includes Synthes integration/transaction costs of $165 million, litigation expense of $89 million and $27 million for the ASR™ Hip program recorded in the fiscal third quarter of 2012. Includes Synthes integration/transaction costs of $388 million, intangible asset write-downs of $146 million, litigation expense of $89 million and $27 million for the ASR™ Hip program recorded in the fiscal nine months of 2012. (4) Amounts not allocated to segments include interest income/(expense), noncontrolling interests and general corporate income/expense. The fiscal nine months of 2013 includes litigation expense of $6 million. The fiscal nine months of 2012 includes currency losses related to the Synthes acquisition of $234 million and litigation expense of $11 million. SALES BY GEOGRAPHIC AREA
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
United States |  | $ | 7,925 |  |  | $ | 7,791 |  |  | 1.7 | %
Europe |  | 4,478 |  |  | 3,983 |  |  | 12.4 |
Western Hemisphere, excluding U.S. |  | 1,842 |  |  | 1,824 |  |  | 1.0 |
Asia-Pacific, Africa |  | 3,330 |  |  | 3,454 |  |  | (3.6 | )
Total |  | $ | 17,575 |  |  | $ | 17,052 |  |  | 3.1 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 29, 2013 |  | September 30, 2012 |  | Percent Change
United States |  | $ | 23,896 |  |  | $ | 22,370 |  |  | 6.8 | %
Europe |  | 13,631 |  |  | 12,342 |  |  | 10.4 |
Western Hemisphere, excluding U.S. |  | 5,530 |  |  | 5,266 |  |  | 5.0 |
Asia-Pacific, Africa |  | 9,900 |  |  | 9,688 |  |  | 2.2 |
Total |  | $ | 52,957 |  |  | $ | 49,666 |  |  | 6.6 | %

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration